Journal of Literature Pharmacy Sciences

1,25-Dihydroxycholecalciferol: Effects on Metabolic Syndrome and Obesity: Traditional Review
1,25-Dihidroksikolekalsiferol: Metabolik Sendrom ve Obezite Üzerindeki Etkiler: Geleneksel Derleme
Hatice Tuğçe BERBEROĞLUa, Aysun HACIŞEVKİb
aDepartment of Nutrition and Dietetics, KTO Karatay University School of Health Sciences, Konya, TURKEY
bDepartment of Biochemistry, Gazi University Faculty of Pharmacy, Ankara, TURKEY
J Lit Pharm Sci. 2021;10(2):257-67
doi: 10.5336/pharmsci.2020-80908
Article Language: EN
Full Text
ABSTRACT
 Metabolic syndrome (MetS) is a medical term used for a combination of abdominal obesity, dyslipidemia, impaired glucose homeostasis and hypertension, of which its prevalence is increasing in the world. Insulin resistance (IR) and abdominal obesity are considered to be the main reasons for metabolic syndrome development. It is also thought that 1,25 dihydroxy cholecalciferol (vitamin D, calcitriol) deficiency generates a risk of metabolic syndrome development. Maintaining a balanced calcium and phosphorus level is the main function of vitamin D. Vitamin D also affects the cardiovascular system, immune system, intestines, brain and pancreas. Vitamin D metabolizing enzymes and vitamin D receptors exist in some cell groups including diverse immune cells such as B cells, T cells, monocytes and antigen presenting cells. Vitamin D deficiency occurs as a consequence of obesity and it is also a risk factor for the development of obesity. The mechanisms underlying the association between obesity and vitamin D deficiency is not fully understood however, the sequestration theory is the most accepted theory that may explain why obese individuals have lower serum 25-hydroxyvitamin D (calcidiol) levels. In addition, calcitriol deficiency may result in adipogenesis by increasing lipogenesis, inducing catecholamine levels and enhancing parathyroid hormone levels. In this review, the relationship between vitamin D deficiency, MetS, obesity and IR is to be reviewed. In addition, possible underlying mechanisms between these disorders and vitamin D deficiency will be examined.

Keywords: Metabolic syndrome; obesity; insulin resistance; vitamin D deficiency; calcitriol
ÖZET
 Metabolik sendrom (MetS), abdominal obezite, dislipidemi, bozulmuş glukoz homeostazı, hipertansiyon kombinasyonu için kullanılan tıbbi bir terimdir ve dünyada yaygınlığı artmaktadır. İnsülin direnci (IR) ve abdominal obezite, metabolik sendrom gelişiminin ana nedenleri olarak kabul edilmektedir. 1,25 dihidroksi kolekalsiferol (D vitamini, kalsitriol) eksikliğinin de metabolik sendrom gelişme riskine katkıda bulunduğu düşünülmektedir. Kalsiyum ve fosfor seviyesini dengeli bir şekilde korumak, D vitamininin temel işlevidir. D vitamini ayrıca kardiyovasküler sistemi, bağışıklık sistemini, bağırsakları, beyni ve pankreası etkilemektedir. D vitamini metabolize eden enzimler ve vitamin D reseptörleri, B hücreleri, T hücreleri, monositler ve antijen sunan hücreler gibi çeşitli bağışıklık hücreleri dâhil olmak üzere bazı hücre gruplarında bulunmaktadır. D vitamini eksikliği obezitenin bir sonucu olarak ortaya çıktığı gibi obezite gelişimi için de bir risk faktörüdür. Obezite ile D vitamini eksikliği arasındaki ilişkinin altında yatan mekanizmalar tam olarak anlaşılamamıştır. Bununla birlikte, sekestrasyon teorisi, obez bireylerin neden daha düşük serum 25-hidroksivitamin D (kalsidiol) seviyelerine sahip olduğunu açıklayabilecek en çok kabul gören teoridir. Ek olarak kalsitriol eksikliği, lipogenezi artırarak, katekolamin seviyelerini indükleyerek ve paratiroid hormon seviyelerini yükselterek adipogeneze neden olabilir. Bu derlemede; D vitamini eksikliği ile MetS, obezite ve IR arasındaki ilişki gözden geçirilecektir. Ek olarak bu bozukluklar ile D vitamini eksikliği arasındaki olası altta yatan mekanizmalar incelenecektir.

Anahtar Kelimeler: Metabolik sendrom; obezite; insülin direnci; D vitamini eksikliği; kalsitriol
REFERENCES:
  1. Çağlayan A, Katlan DC. Vitamin D eksikliğinin ve toksisitesinin maternal-fetal, infant ve çocuk sağlığı üzerindeki zararlı sonuçları [Deleterious outcomes of Vitamin D deficiency and toxicity on maternal-fetal, infant and child health]. J Lit Pharm Sci. 2018;7(3):205-26. [Crossref] 
  2. Reijven PLM, Soeters PB. Vitamin D: A magic bullet or a myth? Clin Nutr. 2020. [PubMed] 
  3. Charoenngam N, Shirvani A, Holick MF. Vitamin D for skeletal and non-skeletal health: What we should know. J Clin Orthop Trauma. 2019;10(6):1082-93. [Crossref]  [PMC] 
  4. Sung CC, Liao MT, Lu KC, Wu CC. Role of vitamin D in insulin resistance. J Biomed Biotechnol. 2012;2012:1-11. [Crossref]  [PubMed]  [PMC] 
  5. Alshahrani F, Aljohani N. Vitamin D: Deficiency, sufficiency and toxicity. Nutrients. 2013;5(9):3605-16. [Crossref]  [PubMed]  [PMC] 
  6. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266-81. [Crossref]  [PubMed] 
  7. Wadhwa S, Sharma DS, Mehta M, Thakur D, Mahajan S, Singh SK, et al. Vitamin D deficiency, skin, and sunshine: A review. Int. J. Green Pharm. 2018;12(2):345-53.
  8. Fu J, Han L, Zhao Y, Li G, Zhu Y, Li Y, et al. Vitamin D levels are associated with metabolic syndrome in adolescents and young adults: The BCAMS study. Clin Nutr. 2019;38(5):2 161-7. [Crossref]  [PubMed] 
  9. Pereira-Santos M, Costa PRF, Assis AMO, Santos CAST, Santos DB. Obesity and vitamin D deficiency: A systematic review and meta-analysis. Obes Rev. 2015;16(4):341-9. [Crossref]  [PubMed] 
  10. Afzal S, Brøndum-Jacobsen P, Bojesen SE, Nordestgaard BG. Vitamin D concentration, obesity, and risk of diabetes: A mendelian randomisation study. Lancet Diabetes Endocrinol. 2014;2(4):298-306. [Crossref]  [PubMed] 
  11. Vranić L, Mikola?ević I, Milić S. Vitamin D deficiency: Consequence or cause of obesity? Medicina. 2019;55(9). [Crossref]  [PubMed]  [PMC] 
  12. Hacışevki A, Berberoğlu HT. Activation of inflammatory signaling pathways in metabolic syndrome: changes in adipokines and cytokines. In book: Current Biochemical Studies. 2020:15-36.
  13. Ye J. Mechanisms of insulin resistance in obesity. Front Med. 2013;7(1):14-24. [Crossref]  [PubMed]  [PMC] 
  14. Gradillas-García A, Álvarez J, Rubio JA, de Abajo FJ. Relationship between vitamin D deficiency and metabolic syndrome in adult population of the Community of Madrid. Endoc rinol Nutr. 2015;62(4):180-7. [Crossref]  [PubMed] 
  15. Bhalwar R. Metabolic syndrome: The Indian public health perspective. Med J Armed Forces India. 2020;76(1):8-16. [Crossref]  [PubMed]  [PMC] 
  16. Botella-Carretero JI, Alvarez-Blasco F, Villafruela JJ, Balsa JA, Vázquez C, Escobar-Morreale HF. Vitamin D deficiency is associated with the metabolic syndrome in morbid obesity. Clin Nutr. 2007;26(5):573-80. [Crossref]  [PubMed] 
  17. Schmitt EB, Nahas-Neto J, Bueloni-Dias F, Poloni PF, Orsatti CL, Petri Nahas EA. Vitamin D deficiency is associated with metabolic syndrome in postmenopausal women. Maturitas. 2018;107:97-102. [Crossref]  [PubMed] 
  18. Mansouri M, Abasi R, Nasiri M, Sharifi F, Vesaly S, Sadeghi O, et al. Association of vitamin D status with metabolic syndrome and its components: A cross-sectional study in a population of high educated Iranian adults. Diabetes Metab Syndr. 2018;12(3):393-8. [Crossref]  [PubMed] 
  19. Prasad P, Kochhar A. Interplay of Vitamin D and metabolic syndrome: A review. Diabetes Metab Syndr. 2016;10(2):105-12. [Crossref]  [PubMed] 
  20. Barbalho SM, Tofano RJ, de Campos AL, Rodrigues AS, Quesada K, Bechara MD, et al. Association between vitamin D status and metabolic syndrome risk factors. Diabetes Metab Syndr. 2018;12(4):501-7. [Crossref]  [PubMed] 
  21. Binobead MA, Al-Qahtani WH, Bader NA Al, Alsedairy SA, Arzoo S. Prevalence of Vitamin D deficiency and the effect of anthropometric and lifestyle factors on theVitamin D statuses of healthy women residing in Riyadh. Progress in Nutrition. 2019;21(2):299-308. [Link] 
  22. Sabuncu T, Bayram F, Kıyıcı S, Satman İ, Yumuk V, İzol AN, et al. Obezite Tanı ve Tadavi Kılavuzu; Ankara: 2018. [Link] 
  23. Nadulska A, Szwajgier D, Opielak G. Obesity and metabolic syndrome. MEDtube Science. 2017;(1):35-44.
  24. WHO [İnternet]. [Erişim tarihi: 28.08.2020]. Obesity. Erişim linki: [Link] 
  25. Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92:6-10. [Crossref]  [PubMed] 
  26. Aktar N, Qureshi NK, Ferdous HS. Obesity: A review of pathogenesis and management strategies in Adult. Delta Med Col J. 2017;5(1): 35-48. [Crossref] 
  27. de Oliveira LF, de Azevedo LG, da Mota Santana J, de Sales LPC, Pereira-Santos M. Obesity and overweight decreases the effect of vitamin D supplementation in adults: systematic review and meta-analysis of randomized controlled trials. Rev Endocr Metab Disord. 2020;21(1):67-76. [Crossref]  [PubMed] 
  28. Hacışevki A, Baba B. An overview of vitamins and minerals in the prevention of COVID-19 infection. Gazi Medical J. 2020;31(3A):523-7. [Link] 
  29. Greco EA, Lenzi A, Migliaccio S. Role of hypovitaminosis D in the pathogenesis of obesity-induced insulin resistance. Nutrients. 2019;11(7):1506. [Crossref]  [PubMed]  [PMC] 
  30. Zaki M, Kamal S, Basha WA, Youness E, Ezzat W, El-Bassyouni H, et al. Association of vitamin D receptor gene polymorphism (VDR) with vitamin D deficiency, metabolic and inflammatory markers in Egyptian obese women. Genes and Dis. 2017;4(3):176-82. [Crossref]  [PubMed]  [PMC] 
  31. Pajor IS, Sliwinska A. Analysis of association between vitamin D deficiency and insulin resistance. Nutrients. 2019;11(4). [Crossref]  [PubMed]  [PMC] 
  32. Rammos G, Tseke P, Ziakka S. Vitamin D, the renin-angiotensin system, and insulin resistance. Int Urol Nephrol. 2008;40(2):419-26. [Crossref]  [PubMed] 
  33. Urrunaga-Pastor D, Guarnizo-Poma M, Macollunco-Flores P, Lazaro-Alcantara H, Paico-Palacios S, Pantoja-Torres B, et al. Asso ciation between vitamin D deficiency and insulin resistance markers in euthyroid non-diabetic individuals. Diabetes Metab Syndr. 2019; 13(1):258-63. [Crossref]  [PubMed] 
  34. Pramono A, Jocken JWE, Blaak EE. Vitamin D deficiency in the aetiology of obesity-related insulin resistance. Diabetes Metab Res Rev. 2019;35(5):e3146. [Crossref]  [PubMed] 
  35. Yaribeygi H, Maleki M, Sathyapalan T, Iranpanah H, Orafai HM, Jamialahmadi T, et al. The molecular mechanisms by which vitamin D improve glucose homeostasis: A mechanistic review. Life Sci. 2020;244:117305. [Crossref]  [PubMed] 
  36. Wimalawansa SJ. Associations of vitamin D with insulin resistance, obesity, type 2 diabetes, and metabolic syndrome. J Steroid Biochem Mol Biol. 2018;175:177-89. [Crossref]  [PubMed] 
  37. Wang W, Zhang J, Wang H, Wang X, Liu S. Vitamin D deficiency enhances insulin resistance by promoting inflammation in type 2 diabetes. Int J Clin Exp Pathol. 2019;12(5): 1859- 67. [PubMed]  [PMC] 
  38. Huang CY, Chang HH, Lu CW, Tseng FY, Lee LT, Huang KC. Vitamin D status and risk of metabolic syndrome among non-diabetic young adults. CliN Nutr. 2015;34(3):484-9. [Crossref]  [PubMed] 
  39. Mehri Z, Salehi-Abargouei A, Shahvazi S, Samadi M, Zare F, Nadjarzadeh A. The association between vitamin D status and metabolic syndrome and its components among female teachers residing in Yazd city. Endocrinol Diabetes Nutr. 2019;66(10):628-38. [Crossref]  [PubMed] 
  40. Parker J, Hashmi O, Dutton D, Mavrodaris A, Stranges S, Kandala NB, et al. Levels of vitamin D and cardiometabolic disorders: Systematic review and meta-analysis. Maturitas. 2010;65(3):225-36. [Crossref]  [PubMed] 
  41. Chen WR, Liu ZY, Shi Y, Yin DW, Wang H, Sha Y, et al. Vitamin D and nifedipine in the treatment of Chinese patients with grades I-II essential hypertension: A randomized placebo- controlled trial. Atherosclerosis. 2014;235(1): 102-9. [Crossref]  [PubMed] 
  42. Larsen T, Mose FH, Bech JN, Hansen AB, Pedersen EB. Effect of cholecalciferol supplementation during winter months in patients with hypertension: A randomized, placebo-controlled trial. Am J Hypertens. 2012;25(11): 1215-22. [Crossref]  [PubMed] 
  43. Chan R, Chan D, Woo J, Ohlsson C, Mellström D, Kwok T, et al. Serum 25-hydroxyvitamin D and parathyroid hormone levels in relation to blood pressure in a cross-sectional study in older Chineses men. J Hum Hypertens. 2012;26(1):20-7. [Crossref]  [PubMed] 
  44. Dadoniene J, Čypiene A, Rinkuniene E, Badariene J, Burca J, Sakaite I, et al. Vitamin D and functional arterial parameters in postmenopausal women with metabolic syndrome. Adv Med Sci. 2016;61(2):224-30. [Crossref]  [PubMed] 
  45. Ahmad YK, El-Ghamry EM, Tawfik S, Atia WM, Keder MM, Abd-El Kader SA. Assessment of Vitamin D Status In Patients With Essential Hypertension. Egypt J Hosp Med. 2018;72(5):4434-8. [Crossref] 
  46. Golzarand M, Shab-Bidar S, Koochakpoor G, Speakman J R, Djafarian K. Effect of vitamin D3 supplementation on blood pressure in adults: An updated meta-analysis. Nutr Metab Cardiovasc Dis. 2016;26(8):663-73. [Crossref]  [PubMed] 
  47. Shab-Bidar S, Bours S, Geusens PPMM, Kessels AGH, van den Bergh JPW. Serum 25(OH)D response to vitamin D3 supplementation: A meta-regression analysis. Nutrition. 2014;30(9):975-85. [Crossref]  [PubMed] 
  48. Kim MR, Jeong SJ. Relationship between vitamin D level and lipid profile in non-obese children. Metabolites. 2019;9(7):125. [Crossref]  [PubMed]  [PMC] 
  49. Wang Y, Si S, Liu J, Wang Z, Jia H, Feng K, et al. The associations of serum lipids with Vitamin D status. PLoS ONE. 2016;11(10): e0165157. [Crossref]  [PubMed]  [PMC] 
  50. Vaskonen T, Mervaala E, Sumuvuori V, Seppänen-Laakso T, Karppanen H. Effects of calcium and plant sterols on serum lipids in obese Zucker rats on a low-fat diet. Br J Nutr. 2002;87(3):239-45. [Crossref]  [PubMed] 
  51. Ford E, Ajani U, McGuire L, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care. 2005;28(5):1228-30. [Crossref]  [PubMed] 
  52. Chaudhuri JR, Mridula KR, Anamika A, Boddu DB, Misra PK, Lingaiah A, et al. Deficiency of 25-Hydroxyvitamin D and Dyslipidemia in Indian Subjects. J Lipids. 2013:1-7. [Crossref]  [PubMed]  [PMC] 
  53. Shivaprakash NC, Joseph RB. Relationships between Serum 25-Hydroxy Vitamin D Levels and Plasma Glucose and Lipid Levels in Pediatric Patients in a Rural. Int J Sci Study. 2014;1(4):24-31.
  54. Rusconi RE, De Cosmi V, Gianluca G, Giavoli C, Agostoni C. Vitamin D insufficiency in obese children and relation with lipid profile. Int J Food Sci Nutr. 2015;66(2):132-4. [Crossref]  [PubMed] 
  55. Rfraf M, Hasanabad SK, Jafarabadi MA. Vitamin D status and its relationship with metabolic syndrome risk factors among adolescent girls in Boukan, Iran. Public Health Nutr. 2014;17(4):803-9. [Crossref]  [PubMed] 
  56. Khan H, Kunutsor S, Franco OH, Chowdhury R. Vitamin D, type 2 diabetes and other metabolic outcomes: A systematic review and meta-analysis of prospective studies. Proc Nutr Soc. 2013;72(1):89-97. [Crossref]  [PubMed] 
  57. Tamer G, Mesci B, Tamer I, Kilic D, Arik S. Is vitamin D deficiency an independent risk factor for obesity and abdominal obesity in women? Endokrynol Pol. 2012;63(3):196-201. [PubMed] 
  58. Bassatne A, Chakhtoura M, Saad R, Fuleihan GEH. Vitamin D supplementation in obesity and during weight loss: A review of randomized controlled trials. Metabolism. 2019;92:1 93-205. [Crossref]  [PubMed] 
  59. Vimaleswaran KS, Berry DJ, Lu C, Tikkanen E, Pilz S, Hiraki LT, et al. Causal relationship between obesity and Vitamin D status: bi-directional mendelian randomization analysis of multiple cohorts. PLoS Medicine. 2013;10(2):1-13. [PubMed]  [PMC] 
  60. Pourshahidi LK. Vitamin D and obesity: Current perspectives and future directions. Proc Nutr Soc. 2015;74(2):115-24. [Crossref]  [PubMed] 
  61. Perna S. Is vitamin d supplementation useful for weight loss programs? A systematic review and meta-analysis of randomized controlled trials. Medicina. 2019;55(7). [Crossref]  [PubMed]  [PMC] 
  62. Gangloff A, Bergeron J, Lemieux I, Després JP. Changes in circulating Vitamin D levels with loss of adipose tissue. Curr Opin Clin Nutr Metab Care. 2016;19(6):464-70. [Crossref]  [PubMed] 
  63. Drincic A, Fuller E, Heaney RP, Armas LAG. 25-Hydroxyvitamin D response to graded vitamin D3 supplementation among obese adults. J Clin Endocrinol Metab. 2013;98(12): 4845-51. [Crossref]  [PubMed] 
  64. Mallard SR, Howe AS, Houghton LA. Vitamin D status and weight loss: A systematic review and meta-analysis of randomized and nonrandomized controlled weight-loss trials. Am J Clin Nutr. 2016;104(4):1151-9. [Crossref]  [PubMed] 
  65. Chakhtoura MT, Nakhoul N, Akl EA, Mantzoros CS, El Hajj Fuleihan GA. Guidelines on Vitamin D replacement in bariatric surgery: Identification and systematic appraisal. Metabolism. 2016;65(4):586-97. [Crossref]  [PubMed]  [PMC] 
  66. Mousa A, Naderpoor N, de Courten MP, Teede H, Kellow N, Walker K, et al. Vitamin D supplementation has no effect on insulin sensitivity or secretion in vitamin D-deficient, overweight or obese adults: a randomized placebo-controlled trial. Am J Clin Nutr. 2017;105(6):ajcn152736. [Crossref]  [PubMed] 
  67. Moreira-Lucas TS, Duncan AM, Rabasa-Lhoret R, Vieth R, Gibbs AL, Badawi A, et al. Effect of vitamin D supplementation on oral glucose tolerance in individuals with low vitamin D status and increased risk for developing type 2 diabetes (EVIDENCE): A double-blind, randomized, placebo-controlled clinical trial. Diabetes Obes Metab. 2017;19(1):133-41. [Crossref]  [PubMed] 
  68. El Hajj C, Chardigny JM, Boirie Y, Yammine K, Helou M, Walrand S. Effect of Vitamin D treatment on glucose homeostasis and metabolism in lebanese older adults: a randomized controlled trial. J Nutr Health Aging. 2018;25(23). [PubMed] 
  69. Vitezova A, Zillikens MC, Van Herpt TTW, Hofman A, Uitterlinden AG, Franco OH, et al. Vitamin D status and metabolic syndrome in the elderly: The Rotterdam Study. Eur J Endocrinol. 2015;172(3):327-35. [Crossref]  [PubMed] 
  70. Bonakdaran S, Fakhraee F, Karimian MS, Mirhafez SR, Rokni H, Mohebati M, et al. Association between serum 25-hydroxyvitamin D concentrations and prevalence of metabolic syndrome. Adv Med Sci. 2016;61(2):219-23. [Crossref]  [PubMed] 
  71. Shafinaz IS, Moy FM. Vitamin D level and its association with adiposity among multi-ethnic adults in Kuala Lumpur, Malaysia: A cross sectional study. BMC Public Health. 2016; 16(232):1-9. [Crossref]  [PubMed]  [PMC] 
  72. Jari M, Qorbani M, Moafi M, Motlagh ME, Keikha M, Ardalan G, et al. Association of 25-hydroxy vitamin D levels with indexes of general and abdominal obesity in iranian adolescents: The CASPIAN-III study. J Res Med Sci. 2015;20(2):122-6. [PubMed]  [PMC] 
  73. Ghaderian B, Shirinpour Z, Aleali AM, Latifi SM, Payami SP, Amani R, et al. Vitamin D level in non-diabetic adult people with metabolic syndrome. Diabetes Metab Syndr. 2019;13(1):236-8. [Crossref]  [PubMed] 
  74. Barzegari M, Sarbakhsh P, Mobasseri M, Noshad H, Esfandiari A, Khodadadi B, et al. The effects of vitamin D supplementation on lipid profiles and oxidative indices among diabetic nephropathy patients with marginal vitamin D status. Diabetes Metab Syndr. 2019;13(1):542-7. [Crossref]  [PubMed] 
  75. Nada AM, Shaheen DA. Cholecalciferol improves glycemic control in type 2 diabetic patients: a 6-month prospective interventional study. Ther Clin Risk Manag. 2017;13:813-20. [Crossref]  [PubMed]  [PMC] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com